Establishment Labs (ESTA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Establishment Labs is set to announce its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.54) per share and revenue of $50.80 million.
• The company's previous earnings report showed a smaller loss than expected at ($0.70) per share, with revenues up 11.3% year-over-year.
• Establishment Labs currently holds a market cap of $1.21 billion, and analysts have a consensus target price of $54.83 with a "Moderate Buy" rating on the stock.

Establishment Labs (NASDAQ:ESTA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $50.80 million for the quarter.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. The firm had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The business's revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.58) EPS. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Establishment Labs Stock Performance

Shares of ESTA stock traded down $0.62 during trading hours on Friday, hitting $41.34. The stock had a trading volume of 316,182 shares, compared to its average volume of 303,225. The stock's 50 day moving average is $40.41 and its 200 day moving average is $36.81. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. The firm has a market capitalization of $1.20 billion, a PE ratio of -13.34 and a beta of 0.83. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $50.85.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ESTA. Needham & Company LLC reissued a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen upgraded shares of Establishment Labs from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Citigroup lifted their price target on Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research note on Wednesday, July 9th. BTIG Research assumed coverage on Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective for the company. Finally, Mizuho upped their price target on shares of Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.83.

Hedge Funds Weigh In On Establishment Labs

A hedge fund recently raised its stake in Establishment Labs stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 20.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,215 shares of the company's stock after buying an additional 9,557 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.20% of Establishment Labs worth $2,335,000 at the end of the most recent quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.